Completed PHASE1 INTERVENTIONAL 2-arm NCT01847989

Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

A Randomized, Placebo-controlled Single-dose, Double-blind Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

Sponsor: Novo Nordisk A/S

Conditions Congenital Bleeding Disorder Congenital FXIII Deficiency Healthy

Interventions catridecacog placebo

Updated 6 times since 2017 Last updated: Jan 10, 2017 Started: Jan 31, 2003 Primary completion: May 31, 2003 Completion: May 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Congenital Bleeding Disorder and Congenital FXIII Deficiency, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berkshire, United Kingdom